Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Plasma autoantibodies against apolipoprotein B-100 peptide 210 in subclinical atherosclerosis.

  • Olga McLeod
  • Angela Silveira
  • Gunilla Nordin Fredrikson
  • Karl Gertow
  • Damiano Baldassarre
  • Fabrizio Veglia
  • Bengt Sennblad
  • Rona J Strawbridge
  • Malin Larsson
  • Karin Leander
  • Bruna Gigante
  • Jussi Kauhanen
  • Rainer Rauramaa
  • Andries J Smit
  • Elmo Mannarino
  • Philippe Giral
  • Steve E Humphries
  • Elena Tremoli
  • Ulf de Faire
  • John Ohrvik
  • Jan Nilsson
  • Anders Hamsten
Publishing year: 2014
Language: English
Pages: 242-248
Publication/Series: Atherosclerosis
Volume: 232
Issue: 1
Document type: Journal article
Publisher: Elsevier

Abstract english

Experimental studies have suggested that autoimmunity is involved in atherosclerosis and provided evidence that both protective and pro-atherogenic immune responses exist. This concept has received support from small clinical studies implicating autoantibodies directed against apolipoprotein B-100 (apoB-100) in human atherosclerosis. We examined circulating autoantibodies directed against native and malondialdehyde (MDA)-modified epitope p210 of apoB-100 (IgG-p210nat and IgM-p210MDA) in relation to early atherosclerosis in a large, European longitudinal cohort study of healthy high-risk individuals.


  • Cardiac and Cardiovascular Systems


  • Cardiovascular Research - Immunity and Athersosclerosis
  • ISSN: 1879-1484
E-mail: jan [dot] nilsson [at] med [dot] lu [dot] se

Lund University Diabetes Centre, CRC, SUS Malmö, Jan Waldenströms gata 35, House 91:12. SE-214 28 Malmö. Telephone: +46 40 39 10 00